{"html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fryamada22.hatenablog.jp%2Fentry%2F20160117%2F1452987121\" title=\"First-in-Human \u306e\u30ea\u30b9\u30af\u30a2\u30bb\u30b9\u30e1\u30f3\u30c8 - ryamada\u306e\u907a\u4f1d\u5b66\u30fb\u907a\u4f1d\u7d71\u8a08\u5b66\u30e1\u30e2\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","version":"1.0","provider_url":"https://hatena.blog","author_url":"https://blog.hatena.ne.jp/ryamada22/","title":"First-in-Human \u306e\u30ea\u30b9\u30af\u30a2\u30bb\u30b9\u30e1\u30f3\u30c8","blog_url":"https://ryamada22.hatenablog.jp/","height":"190","width":"100%","categories":["First-in-Human"],"author_name":"ryamada22","url":"https://ryamada22.hatenablog.jp/entry/20160117/1452987121","published":"2016-01-17 08:32:01","description":"paper(Addressin the Ethical Challenges of First-in-Human Trials) Evaluationg preclinical data PhaseI \u306b\u5165\u308b\u524d\u306e\u30c7\u30fc\u30bf\"preclinical data\"\u306f\u52d5\u7269\u5b9f\u9a13\u3060\u3057\u3001clinical study\u306e\u3088\u3046\u306a\u53b3\u3057\u3044\u5b9f\u9a13\u30c7\u30b6\u30a4\u30f3\u898f\u5b9a\u3082\u306a\u304f\u3001\u30d1\u30d6\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u30d0\u30a4\u30a2\u30b9\u3082\u3042\u308b\u306a\u3069\u3001\u8af8\u554f\u984c\u304c\u3042\u308b Assessing risk \u4f55\u3092\u6e2c\u308b\u3079\u304d\u304b Risk-benefit ratio \u904e\u5270\u306a\u30ea\u30b9\u30af\u304b\u3089\u88ab\u9a13\u8005\u3092\u5b88\u308b\u305f\u3081\u306e\u30ea\u30b9\u30af\u91cf \u300c\u30ea\u30b9\u30af\u300d\u306e\u5b9a\u7fa9\u3084\u3001\u300c\u30ea\u30b9\u30af-\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u6bd4\u300d\u306e\u9069\u5207\u5024\u306f\u7acb\u5834(\u958b\u767a\u8005\u3001IRB(Inst\u2026","provider_name":"Hatena Blog","type":"rich","image_url":null,"blog_title":"ryamada\u306e\u907a\u4f1d\u5b66\u30fb\u907a\u4f1d\u7d71\u8a08\u5b66\u30e1\u30e2"}